2.5. Analysis of clinically actionable genes and drug response associated with disulfidptosis status

The area under the dose-response curve (AUC) data and gene expression matrix for cancer cell lines were downloaded from the Genomics of Drug Sensitivity in Cancer (GDSC) (http://www.cancerrxgene.org/downloads) and Cancer Cell Line Encyclopedia (CCLE). Imputed drug response of 138 antitumor drugs in TCGA cancer patients were download from a previous study [21]. The information of clinically actionable genes targeted by Food and Drug Administration (FDA)-approved drugs was downloaded from a previous study [22]. The drug repurposing information with drug-target was downloaded from The Drug Repurposing Hub (https://clue.io/repurposing-app). To assess drug response in cancer cell lines, we calculated the Spearman correlation between the AUC and gene expression of cancer cell lines from GDSC for drug responsiveness (|Rs| > 0.3; FDR <0.05). To assess the effect of disulfidptosis status on drug sensitivity in TCGA tumor samples, Spearman correlation between imputed drug response and disulfidptosis score we calculated (|Rs| > 0.2; FDR <0.05). Among them, drug resistance showed a positive Spearman correlation, while drug sensitivity showed a negative Spearman correlation.